GlobeNewsWire
03 Nov 2025, 12:00 UTC · 48w ago
Verdict
Headline takes no side. We score CRBU +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Caribou Biosciences' allogeneic CAR-T therapy vispa-cel demonstrated efficacy comparable to autologous therapies, with an 82% overall response rate (ORR) and 64% complete response (CR) rate in a confirmatory cohort.
More positive than 99% of claims this week
Vispa-cel's off-the-shelf nature and tolerability profile may allow for outpatient administration at community hospitals, broadening patient access.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of claims this week
The company identified that using young donor-derived T cells and partial HLA matching (≥2 alleles) optimizes patient outcomes for vispa-cel.
More positive than 65% of claims this week
The therapy demonstrated a generally well-tolerated safety profile, though 55% of all patients experienced cytokine release syndrome (CRS) and 62% experienced thrombocytopenia.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced positive Phase 1 trial data showing that its CAR-T cell therapy has efficacy and durability on par with autologous therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
4h ago
−53.1%
Price is moving against the score
$1.14 vs $2.42 close before publication (Oct 31) · not market-adjusted
CRBU chart →
